GLP-1
-
healthMedicare Delays GLP-1 Weight-Loss Drug Program Amid Insurer Concerns
Medicare will offer GLP-1 weight-loss drugs via a temporary bridge program, delaying a new initiative due to insurer hesitations. Permanent integration remains uncertain.
-
healthTirzepatide Linked to Greater Lean Mass Loss Than Semaglutide in New Analysis
Real-world study reveals tirzepatide patients may lose more lean body mass compared to semaglutide users, impacting metabolic health and aging.
-
healthGLP-1 Drugs Linked to Increased Erectile Dysfunction Risk in Diabetes Patients
A recent study suggests a potential association between GLP-1 receptor agonist use and a higher incidence of erectile dysfunction among men with Type 2 diabetes.
-
healthGenetic Variants May Explain Why GLP-1 Drugs Fail for Some Patients
New research suggests specific genetic variations in the PAM gene could be the reason why GLP-1 medications like Ozempic are ineffective for approximately 10% of individuals with type 2 diabetes.
-
healthNew Study Reveals Unreported Side Effects of Popular Weight-Loss Drugs
A University of Pennsylvania study analyzing Reddit posts uncovers potential new side effects of GLP-1 agonists like Ozempic and Mounjaro, beyond common gastrointestinal issues.
-
healthGut Microbes May Influence Your Food Cravings, Study Suggests
New research explores how the bacteria in your gut could be subtly influencing your dietary preferences and cravings.
-
healthGenetics May Explain Varied Weight-Loss Drug Efficacy
New research suggests genetic factors influence how well individuals respond to popular weight-loss drugs like Ozempic and Mounjaro, offering insights into personalized treatment.
-
healthFDA Approves First Oral GLP-1 Weight-Loss Pill Foundayo
Foundayo is the latest once-daily pill approved for weight loss, offering flexibility without food or water restrictions.